9 new development(s) in neoantigen vaccines today.
Matteo S. Carlino, MD, PhD, FRACP, discussed V940 plus pembrolizumab data, safety, and administration in resected melanoma. CancerNetwork® spoke with Matteo S. Carlino, MD, PhD, FRACP, a medical oncologist at Westmead and Blacktown Hospitals, a faculty member at Melanoma Institut…
MIAMI, Aug. 24, 2026 /PRNewswire/ -- BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting-edge technology, is entering the clinic next quarter. BreakBio aims to be not first-i…
The development of cancer immunotherapy is increasingly moving beyond broadly administered immune checkpoint blockade toward strategies designed around the molecular characteristics of an individual patient’s tumor. A major milestone in this direction has now been reported. On Au…
Relevant work from earlier we're still surfacing — not today's news.